RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
Adipose fat cells and stem cells may help treat hair loss by restoring the scalp's thickness. Treatments like NanoFat injections and Botox are discussed for their potential to promote hair growth.
Human pluripotent stem cells have been used to create hair and skin, potentially offering a new solution for baldness. A user also mentioned starting finasteride but experiencing unexpected hair thinning.
Scientists have grown natural-looking hair from stem cells, potentially revolutionizing hair growth treatments. Concerns include cost, DHT resistance, and the need for future procedures.
HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.
Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.
Stem cell hair transplants use stem cells from fat tissue to reactivate inactive hair follicles, but results are inconsistent and not widely shared. Traditional treatments like finasteride and minoxidil often show better results.
Hair follicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.
Hair loss treatment should target dermal white adipose tissue (DWAT) to restore hair follicles. Potential remedies include tocopherol (vitamin E), botox, rosiglitazone, niacin, kojyl cinnamate esters, and ADP355.
A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.
HairClone is developing cell replacement treatments to rejuvenate and generate hair follicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.
A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
The conversation discusses the importance of scalp skin barrier health in hair follicle cycling, suggesting treatments like ceramides or niacinamide to support hair growth. It also mentions the use of finasteride for hair loss.
The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.
Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
A young male in his twenties discusses hair loss, mentioning the use of Minoxidil, topical finasteride, and occasional derma rolling. He inquires about scalp inflammation, fibrosis, and the potential benefits of magnesium oil and scalp massages for improving blood flow and hair health.
RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.
The conversation discusses using tretinoin for hair loss and whether applying SPF on the scalp is necessary if hair covers the treated areas. The user is considering this treatment despite having no completely bald patches.
A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
Stem cell therapy shows promise in treating hair loss by mimicking DHT-resistant cells from the back of the head. Traditional treatments like finasteride are also discussed, but stem cells could potentially offer a more permanent solution.
A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.
Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.
The conversation is about a hair loss product that claims to use stem cells and ingredients like Capixyl, Redensyl, and Baicapil, with the user asking if anyone has looked into it. No specific treatments were discussed.
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.